secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROCRINE BIOSCIENCES INC (NBIX)
CIK:        0000914475
Form:       8-K
Filed at:   2022-05-23T23:59:59+00:00
Accession:  0000914475-22-000028
Event type: other
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.02, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Neurocrine shareholders approve equity plan amendments, elect directors at 2022 annual meeting
--------------------------------------------------------------------------------

- Three Class II directors elected: Richard Pops, Shalini Sharp, Stephen Sherwin; each received >72M votes.
- Advisory vote on executive compensation passed with 92.76% support.
- Amended and restated 2020 Equity Incentive Plan and ESPP approved (89% and 99.6% of votes cast, respectively).
- Ernst & Young LLP ratified as independent auditor for fiscal 2022 with 93.28% approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/914475/000091447522000028/0000914475-22-000028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/914475/000091447522000028/nbix-20220518.htm
  HTML page:      https://secwatch.observer/filing/0000914475-22-000028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer